A review of paediatric administered radiopharmaceutical activities to determine compliance with prescription guidelines.
Attempts are underway to standardize paediatric administered activities, but equally important is knowing the actual activities administered to patients. In this work, paediatric administered activities are reviewed to determine compliance with the institution-prescribed guidelines. Paediatric administered activities for common studies at our institution, August 2011 to January 2017, have been analysed to determine their deviations from the set guideline tolerance of 10% from prescribed activities. The results for technetium-99m hydroxy diphosphonate (Tc-HDP), technetium-99m mercaptoacetyl triglycine (Tc-MAG3) and technetium-99m dimercaptosuccinic acid (Tc-DMSA), are presented here. Tc-MAG3 mean activities were close to the tolerance guideline at 10.3% SD. For Tc-HDP and Tc-DMSA, the prescribed guidelines were reviewed and reduced in May 2014 and September 2015, respectively. SDs for these studies over the two acquisition periods were different (8.9 and 6.6%, respectively, for Tc-HDP and 11.8 and 14.2%, respectively, for Tc-DMSA).The administered activities (dispensed minus residual activities) to patients depend on prescribed activities and dispensing and injecting techniques. Deviations from the prescribed activities are primarily because of issues related to residual activities, particularly with small activities prescribed in young patients. Small activities in small volumes make residual activities significant. The skill and experience of the nuclear medicine staff are essential in minimizing deviations from prescribed activities. It is important to measure residual to accurately determine the administered activities. If precautions are taken with dispensing and injecting techniques, it is possible to administer activities close to 10% of the prescribed activities. The regular review of the administered activities is essential to ensure that patients are not unnecessarily irradiated.